Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05252702 · ClinicalTrials.gov registry record · NA
Aveir DR i2i Study
A NA study of Bradycardia and Cardiac Pacemaker, Artificial, sponsored by Abbott Medical Devices.
- Active
- Registry status
- NA
- Development phase
- 464
- Enrollment target
- 20
- Study locations
NCT05252702: Active NA study of Bradycardia and Cardiac Pacemaker, Artificial, sponsored by Abbott Medical Devices.
NCT05252702 is a NA study of Bradycardia and Cardiac Pacemaker, Artificial that is active but no longer recruiting, run by Abbott Medical Devices. The registered enrollment target is 464 participants, below the 4,397-participant average among 29 other Bradycardia trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05252702, a NA study of Bradycardia and Cardiac Pacemaker, Artificial, is active but no longer recruiting, sponsored by Abbott Medical Devices.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 464 participants
- Enrollment target
- 20
- Study locations
Study Summary
Prospective, non-randomized, multi-center, international study designed to evaluate the safety and effectiveness of the Aveir™ Dual-Chamber (DR) Leadless Pacemaker system.
Primary Outcome
Aveir DR Leadless Pacemaker system complication-free-rate in de novo subjects. A complication was defined as a device-or-procedure-related serious adverse event. Complications included Atrial LP, Ventricular LP, and implant procedure-related complications. Complications possibly related or related to COVID-19 were excluded.
Conditions Studied
Interventions
- DEVICE Aveir DR Leadless Pacemaker System
Study Locations (20)
California
- Kaiser Permanente Los Angeles Medical Center - Los Angeles
- USC University Hospital - Los Angeles
- Cedars-Sinai Medical Center - Los Angeles
- Premier Cardiology, Inc - Newport Beach
- Providence Medical Foundation - Orange
- Huntington Memorial Hospital - Pasadena
- University of California at San Diego (UCSD) Medical Center - San Diego
- Pacific Heart Institute - Santa Monica
Florida
- Baptist Medical Center - Jacksonville
- Naples Heart Rhythm Specialists, PA - Naples
- AdventHealth Orlando - Orlando
- Sarasota Memorial Hospital - Sarasota
Arkansas
- Arrhythmia Research Group - Jonesboro
- Arkansas Heart Hospital - Little Rock
Georgia
- Piedmont Heart Institute - Atlanta
- Emory University Hospital - Atlanta
Arizona
- HonorHealth - Scottsdale
Colorado
- South Denver Cardiology Associates PC - Littleton
District of Columbia
- Washington Hospital Center - Washington D.C.
Illinois
- Rush University Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 464 participants |
| Start Date | 2022-02-02 |
| Est. Completion | 2025-11 |
| Phase | NA |
What the registry record for NCT05252702 still lists
NCT05252702 is an interventional study that assigns participants to a tested intervention. The registered 464 participants enrollment target is mid-sized for trials with a published cap, below the 4,397-participant average among 29 other Bradycardia trials with a reported enrollment target (89% lower).
The record links to 3 conditions, with Bradycardia appearing as the primary indexed condition, and to 1 intervention - of which Aveir DR Leadless Pacemaker System is the first listed.
NCT05252702 names 20 study sites across 8 states, led by California, Florida, Arkansas.
Frequently Asked Questions
What is clinical trial NCT05252702 about?
NCT05252702 is a clinical study titled "Aveir DR i2i Study". Prospective, non-randomized, multi-center, international study designed to evaluate the safety and effectiveness of the Aveir™ Dual-Chamber (DR) Leadless Pacemaker system.
What is the current status of trial NCT05252702?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 464 participants. The study started on 2022-02-02. Estimated completion is 2025-11.
What conditions does trial NCT05252702 study?
This clinical trial studies the following conditions: Bradycardia, Cardiac Pacemaker, Artificial, Cardiac Rhythm Disorder.
What interventions are being tested in trial NCT05252702?
The interventions under investigation include: Aveir DR Leadless Pacemaker System (DEVICE).
Who is sponsoring clinical trial NCT05252702?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05252702 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bradycardia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05252702's enrollment target sits among peer trials
464 18th of 29 higher than 12 of 29 other Bradycardia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bradycardia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Effect of Womb Recordings on Maturation of Respiratory Control in Preterm Infants
RECRUITING · NA
-
Augmented Pacing for Shock in the Cardiac Intensive Care Unit
RECRUITING · NA
-
BIOTRONIK Conduction System Pacing With the Solia Lead - Solia CSP S
ACTIVE NOT RECRUITING · NA
-
The LEADLESS II IDE Study for the Aveir VR Leadless Pacemaker System
ACTIVE NOT RECRUITING · NA
-
EMRI SureScan™ Clinical Study
COMPLETED · NA
-
ECG Belt to Assess Electrical Synchronization
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04787744 · 464 participants · Phase 2
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
- NCT04855656 · 464 participants · Phase 1
Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors
- NCT06283927 · 464 participants
The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
- NCT06444295 · 464 participants · NA
Testing the Impact of Thrive App Versions on Alcohol Use and Posttraumatic Stress After Recent Sexual Assault
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI